D
Duquesne Family Office LLC
+ HoldingPURR
+9.50%
3M Return
$8.780
+0.101 (+1.15%)At close
Loading chart…
- High
- 8.995
- Open
- 8.600
- VWAP
- 8.78
- Volume
- 11.26M
- Mkt Cap
- —
- Low
- 8.550
- Amount
- 98.84M
- EV/EBITDA, TTM
- 0.33
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
AI analysis of Hyperliquid Strategies Inc (PURR)
BuyHyperliquid Strategies Inc (PURR) is a good buy right now due to its recent stock buyback program expansion to $100 million, which signals strong confidence from the Board in the company's future. Additionally, the stock has shown impressive long-term performance with a 1-year change of +596.83%. However, the current RSI is at 29.95, indicating that the stock is oversold, which could present a buying opportunity. The main risk is the forward P/E ratio of 14.20, which suggests that the stock may be overvalued if future earnings do not meet expectations.
Valuation Metrics
The current forward P/E ratio for Hyperliquid Strategies Inc (PURR) is 14.20, compared to its 5-year average forward P/E of 14.20.
Whales holding PURR
Events Timeline
News
9.510-23NewsfilterHyperliquid Strategies to Host Earnings Webcast on November 5, 2026
8.010-23PRnewswireHyperliquid Increases Stock Buyback Program to $100 Million
- 8.010-23Newsfilter
Hyperliquid Increases Stock Repurchase Program to $100 Million
9.510-23PRnewswireHyperliquid Strategies to Present Q3 Financial Results on November 5
8.510-16CNBCValuation Gap Widens Between AI Leaders OpenAI and Anthropic
PURR FAQ — answered by Alphio AI
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. It operates in the Technology sector.
Hyperliquid Strategies Inc (PURR) is a good buy right now due to its recent stock buyback program expansion to $100 million, which signals strong confidence from the Board in the company's future. Additionally, the stock has shown impressive long-term performance with a 1-year change of +596.83%. However, the current RSI is at 29.95, indicating that the stock is oversold, which could present a buying opportunity. The main risk is the forward P/E ratio of 14.20, which suggests that the stock may be overvalued if future earnings do not meet expectations.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.